Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
March 10th, 2021
4.9K views
The protocol describes experimental methods to obtain stable major histocompatibility complex (MHC) class I through potential β2-microglobulin (β2m) substitutions from different species. The structural comparison of MHC I stabilized by homologous and heterologous β2m were investigated.
Overview
This study presents a methodology for obtaining stable major histocompatibility complex (MHC) class I using 尾 2 -microglobulin (尾 2 m) substitutions from various species. It evaluates the structural and functional implications of hybrid MHC class I complexes.
Key Study Components
Area of Science
- Immunology
- Structural Biology
- Biotechnology
Background
- MHC class I molecules are crucial for immune response.
- 尾 2 -microglobulin is a key component in MHC stability.
- Previous research indicates that substitutions can maintain peptide presentation.
- Hybrid MHC class I may mimic original structures and functions.
Purpose of Study
- To assess the feasibility of hybrid MHC class I with heterologous 尾 2 m.
- To explore the structural stability of MHC I complexes.
- To facilitate studies on tissue responses in immunotherapy.
Methods Used
- Utilized Bat MHC Class I as a model for experimentation.
- Conducted E. coli culture transformation with plasmids.
- Performed heat shock and incubation techniques for bacterial transformation.
- Analyzed structural and functional properties of MHC I complexes.
Main Results
- Hybrid MHC class I retains similar structure and function to original molecules.
- Substitutions do not significantly affect peptide presentation.
- Methodology supports further research in infectious disease and tumor immunotherapy.
- Successful transformation of E. coli with bat or human MHC Class I components.
Conclusions
- Hybrid MHC class I complexes are viable for research applications.
- 尾 2 m substitutions can stabilize MHC I without loss of function.
- This approach can enhance understanding of immune responses in various contexts.
Frequently Asked Questions
What is the significance of MHC class I?
MHC class I molecules are essential for presenting peptides to CD8+ T cells, playing a critical role in the immune response.
How does 尾 2 -microglobulin affect MHC stability?
尾 2 -microglobulin is crucial for the structural integrity and stability of MHC class I molecules.
What are the applications of hybrid MHC class I?
Hybrid MHC class I can be used in studies related to infectious diseases and cancer immunotherapy.
What methods were used to transform E. coli?
The study utilized heat shock and incubation techniques for the transformation process.
What were the main findings of the study?
The study found that hybrid MHC class I retains functionality and can be effectively used in research.
Can substitutions in 尾 2 m affect peptide presentation?
Previous studies indicate that substitutions do not significantly impact peptide presentation.
What is the next step for this research?
Further studies will explore the implications of hybrid MHC class I in various immunological contexts.
Executive Industry Relevance
This methodology enables structural and functional analysis of MHC class I when homologous beta-2 microglobulin is unavailable, supporting target validation in immunology and immunotherapy research. By demonstrating that heterologous beta-2 microglobulin substitution preserves peptide binding and complex stability, the approach reduces biological risk in early discovery. It provides a reusable platform for evaluating immune targets in infectious disease and tumor immunotherapy pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of MHC I structure and function when species-matched beta-2 microglobulin is not accessible.
- Operational Value: Uses standard recombinant protein expression and purification workflows compatible with existing biopharma infrastructure.
- Predictive Value: Supports target confidence by showing hybrid complexes maintain peptide binding groove integrity and T cell recognition potential.
Screening & Assay Development
- Scientific Value: Produces stable, refolded MHC I-peptide complexes suitable for binding and structural assays.
- Operational Value: Generates quantifiable protein yields (15 mg/mL) enabling reproducible biophysical and biochemical screening.
- Assay Readiness: Facilitates crystallization and structural determination for epitope mapping and inhibitor design.
Translational & Preclinical Research
- Scientific Value: Enables evaluation of T cell responses by preserving antigen presentation capability across species.
- Operational Value: Provides a continuous workflow from gene expression to structural validation for preclinical target assessment.
- Risk Mitigation: Reduces dependency on species-specific reagents, improving reproducibility in cross-model studies.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead identification to preclinical evaluation, particularly for immunotherapy target assessment.
- Discovery Biology: Supports hypothesis testing of MHC I-peptide interactions and immune evasion mechanisms.
- Screening: Enables production of homogeneous MHC I complexes for binding assays and thermal stability screening.
- Analytics: Provides structural data (RMSD <0.25 Å) and binding capacity metrics to compare complex variants.
- Translational Research: Connects structural stability to functional outcomes in T cell activation models.
- Enterprise Reuse: Establishes a platform for MHC I characterization applicable across multiple targets and disease areas.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through structural and functional conservation.
- Operational Value: Standardized refolding and purification process ensures batch-to-batch consistency.
- Strategic Value: Enables go/no-go decisions based on structural fidelity rather than species-matched reagent availability.
- Portfolio Impact: Supports risk-adjusted prioritization of immunotherapy targets by enabling early structural de-risking.
Implementation Considerations
- Requires expertise in recombinant protein expression, inclusion body refolding, and structural biology techniques.
- Depends on access to centrifugation, sonication, chromatography, and crystallization equipment.
- Necessitates standardized protocols for glutathione-based refolding and peptide dosing to ensure complex stability.
- Requires optimization across species due to potential variations in expression yield and refolding efficiency.
- Limited by the need for high-purity inclusion bodies and appropriate peptide solubility in DMSO for successful refolding.
Biopharma FAQs
Why does beta-2 microglobulin substitution matter for MHC I target validation?
Heterologous beta-2 microglobulin substitution enables structural and functional studies of MHC I when homologous light chains are unavailable, preserving peptide binding capacity and complex stability as demonstrated by comparable RMSD values and peptide binding assays.
How does isolation of the MHC heavy chain variable contribute to discovery pipeline de-risking?
Isolating and refolding the MHC heavy chain with defined beta-2 microglobulin allows controlled assessment of peptide binding groove integrity, reducing uncertainty in target validation before committing to downstream screening campaigns.
What quantitative measurements enable assessment of MHC I complex stability?
Protein thermostability measurements, structural superposition RMSD (<0.25 Å), and peptide binding capacity assays provide quantitative metrics to evaluate complex stability and functional equivalence across beta-2 microglobulin sources.
Why are replication requirements critical for MHC I complex production in collaborative settings?
Reproducible refolding yields and consistent structural data across replicates ensure reliable data sharing between discovery, structural biology, and immunology teams, supporting go/no-go decisions based on validated complex production.
What analytical capabilities are required before implementing heterologous beta-2 microglobulin substitution in MHC I studies?
Implementation requires access to protein quantification, SDS-PAGE for purity assessment, size-exclusion chromatography for complex isolation, and X-ray diffraction or binding assays to confirm structural and functional integrity of the refolded MHC I complex.
Chapters in this video
0:04
Introduction
0:54
E. coli Transformation
1:46
Culture Inoculation
2:59
Bacteria Harvest
3:28
Inclusion Body Purification
4:27
MHC Complex Refolding
4:53
MHC H Chain and Beta2m Injection and Dilution
5:42
Refolded Protein Concentration Determination
6:51
Crystallization, Data Collection, and Processing
7:41
Structure Determination and Analyses
8:33
Results: Representative Bat MHC I Beta2-Microglobulin Stability and Structure Analysis
10:21
Conclusion
